| April 2009 – Dr. David C. U’Prichard, Venture Partner of Red Abbey Ventures and former CEO of 3DP, chair of R&D at SmithKline Beecham,
and other pharma and biotech companies, joins Naurex’s Science Advisory Board and Board of Directors. |
| April 2009 – Falk Center for Molecular Therapeutics, the Northwestern University lab of Naurex founder Dr. Joseph Moskal,
awarded an industry grant for development of 1st generation NMDA program GLYX-13 in various CNS disorders. |
| March 2009 – Naurex Founder and Chief Scientist Dr. Joseph Moskal, Northwestern Falk Center collaborators Drs. Jeffrey
Bergdorff and Roger Kroes, and colleagues awarded the Frank A. Beach Comparative Psychology Award for their 2008 paper in the Journal of
Comparative Psychology. |
| March 2009 – Dr. Frank Menitti, former Research Fellow at Pfizer, joins Naurex’s Science Advisory Board. |
| December 2008 – Naurex and collaborators publish a paper in the journal Neuropharmacology reporting novel mechanism of
action of GLYX-13 both increasing LTP and supressing LTD (Zhang, et al, Neuropharmacology 2008). |
| October 2008 – Dr. Ronald Burch, veteran biotech and pharma drug developer of more than 20 years at Zeneca, Purdue,
Rhone Poulenc-Rorer, Pacira, AlgoRx, Nova, and others, joins Naurex’s SAB and management team as Chief Medical Advisor. |
| August 2008 – Naurex publishes a paper in the journal NeuroReport on the efficacy and safety of 1st generation lead NMDA
Receptor modulator GLYX-13 in preclinical models of neuropathic pain (Wood, et al, NeuroReport 2008) |
| August 2008 – Dr. J. David Leander, former chair of Neuroscience Discovery group at Eli Lilly, joins Naurex’s Science Advisory
Board and management team as Chief Scientific Advisor. |
| June 2008 – Dr. George Miljanich, CEO of Airmid and recent past director of Elan’s Prialt program, joins Naurex’s Science
Advisory Board. |
| March 2008 – Naurex re-capitalizes and launches to develop novel NMDA drug programs to treat multiple disorders of the central
nervous system (CNS); Derek Small of Luson Bioventures joins the board of directors and management team. |
